The studies must include the following requirements:

randomized controlled trail and retrospective cohort study;

The patients were diagnosed as PC (with or without bone metastasis);

All patients received 68Ga-PSMA-PET/CT and bone scan, the gold standard is determined by pathological analysis and/or clinical and imaging follow-up;

study compared the diagnostic value of 68Ga-PSMA-PET/CT and bone scan.

studies provided original diagnostic data (SEN, SPE), positive likelihood ratio [+LR], negative likelihood ratio [–LR], Diagnostic odds ratio [DOR], area under curve [AUC]) or can be calculated using enough evidence;

The report time of the study is from inception to March 31, 2020.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.